Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Dilemmas in TD in Primary Care

In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.

W. Clay Jackson, MD, DipTh
Greg W. Mattingly, MD
Released: August 20, 2021

Information on this Educational Activity

Faculty

W. Clay Jackson, MD, DipTh

Assistant Professor of Clinical Family Medicine & Psychiatry
College of Medicine
University of Tennessee
Director
Palliative Care
West Cancer Center
Memphis, Tennessee

W. Clay Jackson, MD, DipTh, has disclosed that he has received consulting fees from AbbVie, Alkermes, Genentech, Otsuka, and Sunovion.
Greg W. Mattingly, MD

Associate Clinical Professor
Psychiatry
Washington University School of Medicine
St Louis, Missouri
President
Midwest Research Group
St. Louis, Missouri

Greg Mattingly, MD, has disclosed that he has received consulting fees from AbbVie, Acadia, Alkermes, Axsome, Eisai, Ironshore, Intracellular, Janssen, Lundbeck, Neos, Neurocrine, Otsuka, Redax, Roche, Rhodes, Sage, Shire, Sunovion, Supernus, Takeda, Teva, and Trispharma; funds for research support from AbbVie, Acadia, Alkermes, Avanir, Axsome, Boehringer Ingelheim, Emalex, Janssen, Medgenics, NLS-1 Pharma AG, Redax, Roche, Sage, Shire, Sunovion, Supernus, Takeda, and Teva; and fees for non-CME/CE services from AbbVie, Alkermes, Eisai, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, and Trispharma.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant provided by
Neurocrine Biosciences, Inc.

Related Content

Board-certified psychiatric pharmacist provides information on the pharmacokinetics and administration of long-acting injectable antipsychotics, from Clinical Care Options (CCO)

Austin Campbell, PharmD, BCCP Released: January 24, 2023

In this on-demand webcast, an expert faculty explores updates on identifying and managing tardive dyskinesia.

Leslie Citrome, MD, MPH Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME Credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: January 23, 2023 Expired: January 22, 2024

In this on-demand webcast, an expert faculty describes the current and emerging treatment options for major depression

Greg W. Mattingly, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: 1.0 AAPA Category 1 CME Credit Psychologists: 1.0 APA CE Credit Social Workers: 1.0 ACE CE Credit Released: January 20, 2023 Expired: January 19, 2024

Two psychiatrists discuss the clinical use of long-acting injectable antipsychotics, from Clinical Care Options (CCO)

Leslie Citrome, MD, MPH person default Adam Lowy, MD Released: January 18, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings